Evofem, Aditxt sign amended merger with $1.8M cash and preferred stock

Evofem Biosciences, Inc.

Aditxt to pay up to $1.8M cash for Evofem common stock, less dissenting shares; preferred stock exchange also specified.
Aditxt commits to purchase $4M of Evofem Series F-1 Preferred Stock in staged tranches by Sept 30, 2024.
Merger conditions include shareholder approvals, warrant exchanges, and $150K cap on warrant cash-outs.
Evofem board unanimously recommends merger; proxy statement to be filed with SEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.